Compensated cirrhosis is the early, stable stage of cirrhosis where the liver is scarred but still functions well enough to perform its essential jobs. People at this stage often feel fine and may not even know they have cirrhosis. The median survival for compensated cirrhosis is over 12 years, and the one-year survival rate is around 95%, making it a very different situation from the more severe decompensated stage.
How the Liver Compensates for Damage
Cirrhosis means that healthy liver tissue has been replaced by scar tissue (fibrosis) over months or years, usually from chronic hepatitis B or C infection, long-term heavy alcohol use, or fatty liver disease. In the compensated stage, enough functioning liver cells remain to handle the organ’s critical tasks: filtering toxins from the blood, producing proteins that help with clotting and fluid balance, processing nutrients, and making bile for digestion.
The word “compensated” simply means the liver is still keeping up. It’s working harder with less healthy tissue, but lab results and liver function often look close to normal. This is what separates it from decompensated cirrhosis, where the liver can no longer maintain those functions and serious complications develop.
Symptoms You Might Notice
About 40% of people with cirrhosis have no symptoms at all, and the condition is discovered incidentally through routine blood work, imaging, or even at autopsy. This is especially true in the compensated stage.
When symptoms do appear, they tend to be vague and easy to attribute to other causes: fatigue, weakness, loss of appetite, unexplained weight loss, and general malaise. Some people develop small, visible clusters of tiny blood vessels on the skin called spider angiomas, most commonly on the chest and face. Bone thinning from poor vitamin D absorption can also occur over time. None of these symptoms are dramatic enough to immediately suggest cirrhosis, which is why so many cases are caught late.
How Compensated Cirrhosis Is Diagnosed
Diagnosis typically involves a combination of blood tests, imaging, and sometimes a liver biopsy. A few tools are especially useful for identifying cirrhosis before complications develop.
Liver stiffness measurement: A specialized ultrasound called transient elastography (often known by the brand name FibroScan) measures how stiff the liver is, reported in kilopascals (kPa). A reading of 17.6 kPa or higher strongly suggests cirrhosis, with about 97% specificity. Lower values, around 12.5 kPa, point to severe fibrosis that hasn’t yet reached the cirrhosis threshold.
FIB-4 index: This is a simple calculation using your age, platelet count, and two common liver enzymes from a standard blood draw. A score of 3.48 or higher is used to identify cirrhosis-level fibrosis with high confidence, while a score below 1.67 generally rules out advanced fibrosis.
Child-Pugh score: This scoring system grades the severity of cirrhosis from Class A (good function) through Class C (advanced dysfunction) based on bilirubin, albumin, clotting time, and the presence of complications. Compensated cirrhosis corresponds to Child-Pugh Class A, with a score of 5 to 6 points. Bilirubin under 2 mg/dL and albumin above 3.5 g/dL are the benchmarks for the best scores in those categories.
The Stages Within Compensated Cirrhosis
Not all compensated cirrhosis carries the same risk. Clinicians recognize two distinct sub-stages based on whether increased pressure in the veins around the liver (portal hypertension) has begun causing physical changes.
In Stage 1, there are no enlarged veins (varices) in the esophagus or stomach. The one-year mortality rate at this point is just 1%. In Stage 2, varices have formed but haven’t bled. The one-year mortality rate rises modestly to about 3%. Both stages are still considered compensated because no major complications have occurred, but Stage 2 signals that portal pressure is climbing and closer monitoring is warranted.
The five-year mortality picture tells a similar story. For compensated patients without significant portal hypertension, the five-year mortality rate is only 1.5%. With portal hypertension but no varices, it’s about 5%. Once varices are present, it rises to 10%. These numbers highlight that managing portal pressure is one of the most important factors in long-term outcomes.
What Decompensation Looks Like
Each year, roughly 5% to 7% of people with compensated cirrhosis cross into the decompensated stage. This transition is defined by the appearance of specific complications, not by a single lab value or scan result. The three hallmark events are ascites (fluid buildup in the abdomen), variceal bleeding (ruptured veins in the esophagus or stomach), and hepatic encephalopathy (confusion and cognitive changes from toxin buildup).
The shift is dramatic. Median survival drops from over 12 years in the compensated stage to roughly 1.8 years after the first decompensation event. One-year survival falls from 95% to about 61%. Once ascites develops, the one-year mortality rate jumps to around 20%. If variceal bleeding occurs, it reaches approximately 57%. This is why keeping cirrhosis in the compensated phase for as long as possible is the central goal of treatment.
Treating the Underlying Cause
The single most impactful thing you can do with compensated cirrhosis is eliminate whatever caused the liver damage in the first place. For hepatitis C, antiviral treatment can clear the virus and, in many cases, allow some degree of scar tissue to regress over time. For alcohol-related cirrhosis, complete abstinence is critical. For fatty liver disease, sustained weight loss and metabolic management are the primary levers.
Removing the ongoing source of injury doesn’t erase cirrhosis overnight, but it stops the accumulation of new scar tissue and gives the liver its best chance to stabilize or even partially heal. People who successfully treat the underlying cause have significantly lower rates of progression to decompensation.
Diet, Exercise, and Muscle Preservation
Malnutrition and muscle loss are common in cirrhosis, even in the compensated stage, and both independently worsen outcomes. European nutrition guidelines recommend a daily intake of 1.2 to 1.5 grams of protein per kilogram of body weight, which is notably higher than the standard recommendation for healthy adults (about 0.8 g/kg). For a 70-kilogram (154-pound) person, that means 84 to 105 grams of protein per day. Calorie targets are similarly elevated, at 35 to 40 calories per kilogram daily, to prevent the body from breaking down muscle for energy.
Physical activity matters too. Research on compensated cirrhosis patients suggests a practical target of walking at least 5,000 steps per day, combined with adequate calorie intake of about 30 calories per kilogram of ideal body weight. The goal isn’t intense exercise but consistent movement to maintain muscle mass, improve insulin sensitivity, and support overall liver health.
Ongoing Monitoring and Screening
People with cirrhosis of any stage have an elevated risk of developing liver cancer (hepatocellular carcinoma). Guidelines from all major liver disease organizations recommend screening every six months with an abdominal ultrasound combined with a blood test for alpha-fetoprotein, a protein that can rise with liver tumors. This semiannual schedule is based on tumor growth rates and has been shown to detect cancers at earlier, more treatable stages compared to annual screening. This screening is lifelong, even if the underlying cause of cirrhosis has been treated.
Beyond cancer screening, regular monitoring of portal hypertension is important. An upper endoscopy can check for varices, and liver stiffness measurements can help track changes over time. Higher stiffness values correlate with more severe portal hypertension: readings above 27.5 kPa are associated with significant varices, while values above 37.5 kPa suggest the liver function is deteriorating toward a more advanced stage.
Long-Term Outlook
Compensated cirrhosis is a serious diagnosis, but the numbers are more reassuring than many people expect. Median survival exceeds 12 years, and for those without significant portal hypertension, five-year mortality is under 2%. The trajectory depends heavily on whether the underlying cause is addressed and whether decompensation can be prevented.
The 5% to 7% annual transition rate to decompensation is not fixed. It varies based on whether liver injury is ongoing, how well portal hypertension is managed, and individual factors like body composition and overall health. People who eliminate the cause of their liver disease, maintain good nutrition, stay physically active, and keep up with regular screening give themselves the best chance of remaining in the compensated stage for years or even decades.